Waldenstrom’s Macroglobulinemia and Peripheral Neuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes with a Bleeding Diathesis and Rash | Zendy

S. Haider | Zendy; Tahir Latif | Zendy; A. Hochhausler | Zendy; Fred V. Lucas | Zendy; Nagla Abdel Karim | Zendy

Open Access

Waldenstrom’s Macroglobulinemia and Peripheral Neuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes with a Bleeding Diathesis and Rash

Author(s) -

S. Haider,

Tahir Latif,

A. Hochhausler,

Fred V. Lucas,

Nagla Abdel Karim

Publication year - 2013

Publication title -

case reports in oncological medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.173

H-Index - 7

eISSN - 2090-6714

pISSN - 2090-6706

DOI - 10.1155/2013/890864

Subject(s) - medicine , organomegaly , gammopathy , waldenstrom macroglobulinemia , polyneuropathy , macroglobulinemia , bone marrow , peripheral neuropathy , pathology , skin biopsy , poems syndrome , gastroenterology , biopsy , hematology , paraproteins , monoclonal , multiple myeloma , immunology , lymphoma , endocrinology , monoclonal antibody , antibody , diabetes mellitus

We report a case of a 29-year-old male who presented with paraesthesia and skin lesions with excessive bleeding after skin biopsy leading to hematology consultation. He was found to have prolonged partial thromboplastin time (PTT) and monoclonal gammopathy on serum protein electrophoresis (SPEP). He experienced excessive bleeding leading to hospitalization after bone marrow biopsy and required blood transfusion. He was diagnosed with Waldenstrom's Macroglobulinemia (WM), based on the presence of IgM- κ type monoclonal (M) protein and infiltration of lymphoplasmacytic cells identified in bone marrow aspirates. He was noticed to have features of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS syndrome). This is a very rare case of WM with POEMS syndrome which responded to chemotherapy using bortezomib, steroids, and rituximab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research